Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

Anti-drug antibodies were rare and had no apparent impact on itepekimab drug levels. Sanofi and Regeneron are reviewing the data and will discuss with regulatory authorities to evaluate next steps.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Last week, Sanofi and Regeneron reported the failure of a phase 3 trial of their chronic obstructive pulmonary disorder (COPD) candidate itepekimab. In February, Sanofi revealed a phase 3 trial of ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where ...

Regeneron Pharmaceuticals declined by 16.7 percent last week as investors sold off positions amid the surprising failure of ...